Relistor Review Offers Glimpse Into FDA’s Evolving Approach To QT Studies
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA’s review of Wyeth and Progenics’ Relistor (methylnaltrexone) illustrates the agency’s efforts to improve its review of the "thorough QT studies" that FDA requires for all new chemical entities.